A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

NCT07233850 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric/Gastroesophageal Junction Adenocarcinoma
Metastatic Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Oesophageal Cancer

Interventions

DRUG: SSGJ-706+XELOX
DRUG: SSGJ-706+Bevacizumab+XELOX
DRUG: SSGJ-706+AG
DRUG: SSGJ-706+TP

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.